Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Net Income towards Common Stockholders (2024 - 2026)

Maze Therapeutics' Net Income towards Common Stockholders history spans 3 years, with the latest figure at -$24.2 million for Q1 2026.

  • On a quarterly basis, Net Income towards Common Stockholders rose 26.16% to -$24.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$122.5 million, a 148.66% decrease, with the full-year FY2025 number at -$131.1 million, down 3950.81% from a year prior.
  • Net Income towards Common Stockholders hit -$24.2 million in Q1 2026 for Maze Therapeutics, up from -$34.6 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for MAZE hit a ceiling of $13.9 million in Q2 2024 and a floor of -$34.6 million in Q4 2025.
  • Historically, Net Income towards Common Stockholders has averaged -$22.2 million across 3 years, with a median of -$27.7 million in 2024.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 514.43% in 2025 and later increased 26.16% in 2026.
  • Tracing MAZE's Net Income towards Common Stockholders over 3 years: stood at -$5.6 million in 2024, then tumbled by 514.43% to -$34.6 million in 2025, then rose by 29.97% to -$24.2 million in 2026.
  • Business Quant data shows Net Income towards Common Stockholders for MAZE at -$24.2 million in Q1 2026, -$34.6 million in Q4 2025, and -$30.1 million in Q3 2025.